Most Part D plans require a current BMI measurement documented at a recent clinical visit, ICD-10 codes for any qualifying conditions, a record of structured nutrition and physical activity, and the prescribing clinician's prior authorization request
Industry developments include AbbVies USD2.23 billion deal with Gubra A/S to develop an amylin-targeting obesity drug, and Eli Lillys strategic price reduction for its weight-loss drug Zepbound to maintain market share
Even without workouts, it may still support energy metabolism and cognitive function
Although the meta-regression did not significantly reduce the overall heterogeneity, it confirms that the high heterogeneity is driven by a combination of multiple factors rather than a single dominant study feature
The GLP-1 Drug Market is also influenced by innovations in drug delivery systems, with over 48% of new prescriptions shifting toward once-weekly formulations for better patient adherence